Adding ibrutinib to rituximab improved outcomes in patients with previously untreated FL who were ineligible for CIT.

Clinical trials that have shown improved event-free survival were inconsistent regarding overall (all-cause) survival. We aimed to evaluate the effects of maintenance therapy with rituximab on overall ...